P1049 - PICC POTENTIAL FOR SEPSIS AND INFLUENCE OF TAUROLIDINE LOCK

Linked sessions

P1049

PICC POTENTIAL FOR SEPSIS AND INFLUENCE OF TAUROLIDINE LOCK

F. Mario1,*, M. Ocana1, L. Guerrero1

1Nutritional Support, Nutrimedic, Callao, Peru

 

Rationale: PICC were reported safe and efficient for TPN(1). We reported 156 PICC and 228 tunneled CVC for TPN and for 24 months there were 27 and 32 bacteremic episodes for PICC and tunneled CVC (TCVC) respectively and without septicemia. Later on we reported,101 PICC, so when PICC was feasible, it had less risk for sepsis than TCVC, as bacteremia occurred in 5 PICC patients without sepsis and in 26 TCVC patients with 3 septic cases (p<0.01). In 2023 we reported (2) 1/11 PICC with culture positive with 11/11 bacteria positive with SEM. We wished to study with SEM PICC interaction with bacteria and biofilms and its septic potential and taurolidine (TaurolockTM) .

Methods: 2.5 cc of taurolidine were applied for 10 minutes every 5 days, after 10 minutes taurolidine was withdrawn without flushing.  Distal tip of the withdrawn catheters were split open longitudinally for Surface Scanning Electron Microscopy(SEM). 

Results: 15 PICC were studied with SEM, 11 without and 4 with taurolidine. In 15/15 PICC, bacteria and biofilms were clearly identified in every PICC studied. In every PICC bacteria and biofilms were present, those with taurolidine had been clearly affected so survival was jeopardized. 8/72 photos were chosen, 4 w/o taurolidine and 4 with taurolidine.

Conclusion: In this preliminary study, on PICC potential for sepsis, there is clear anti-bacterial protection and against biofilms, from taurolidine.

References: 1) Alhimyary A, Fernandez C, Picard M et al Safety and efficacy of total parenteral nutrition delivered via a peripherally inserted central venous catheter. Nut Clin Pract. 1996; 11(5):199-203

 

2) Ocaña,M, Ferreyra, M, Alegre A et al Biological behaviour of biofilm in catheters for parenteral nutrition (TPN) with and without intravenous therapy. ESPEN 23-ABS-2038. ESPEN Congress, Lyon, France 2023.

Disclosure of Interest: None declared